Stock listing
NASDAQ:LRMR Larimar Therapeutics, Inc. Stock
Home listing (NASDAQ) of Larimar Therapeutics, Inc.
Follow Larimar Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LRMR
$3.14 USD -0.08 (-2.6%)
Close on Nov 20, 2026
- Day range
- $2.96 – $3.22 USDNov 20, 2026
- Volume
- 1.71M sharesNov 20, 2026
- Market cap
- $328.6M USDAt the close on Nov 20, 2026 · price × 104.6M shares outstanding
- 52-week range
- $1.92 – $6.42 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.11M USDMedian day 1.14M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LRMR · Home | $3.14 USD | -0.085 (-2.6%) | 1,707,224 | $3.15 | $3.22 | $2.96 | $3.225 | Close on Nov 20, 2026 |
| Frankfurt:ZA71 | €2.86 EUR | -0.10 (-3.4%) | — | €2.86 | €2.86 | €2.86 | €2.96 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LRMR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.14 | -0.085 | -2.6% | $3.15 | $3.22 | $2.96 | 1,707,224 | |
| $3.225 | +0.235 | +7.9% | $2.95 | $3.345 | $2.93 | 1,405,708 | |
| $2.99 | -0.01 | -0.3% | $3.01 | $3.13 | $2.90 | 1,376,889 | |
| $3.00 | -0.02 | -0.7% | $3.02 | $3.29 | $2.885 | 2,737,345 | |
| $3.02 | +0.32 | +11.9% | $3.01 | $3.075 | $2.835 | 2,531,399 | |
| $2.70 | -0.03 | -1.1% | $2.71 | $2.76 | $2.51 | 1,190,176 | |
| $2.73 | +0.04 | +1.5% | $2.69 | $2.83 | $2.60 | 1,156,891 | |
| $2.69 | +0.16 | +6.3% | $2.58 | $2.735 | $2.46 | 737,802 | |
| $2.53 | +0.14 | +5.9% | $2.47 | $2.58 | $2.37 | 693,309 | |
| $2.39 | +0.07 | +3.0% | $2.355 | $2.475 | $2.30 | 973,590 | |
| $2.32 | -0.44 | -15.9% | $2.76 | $2.83 | $2.265 | 1,772,574 | |
| $2.76 | +0.22 | +8.7% | $2.60 | $2.78 | $2.575 | 1,991,446 | |
| $2.54 | +0.17 | +7.2% | $2.39 | $2.62 | $2.37 | 1,648,267 | |
| $2.37 | -0.10 | -4.0% | $2.49 | $2.566 | $2.34 | 667,387 | |
| $2.47 | -0.20 | -7.5% | $2.64 | $2.655 | $2.42 | 777,010 | |
| $2.67 | +0.13 | +5.1% | $2.57 | $2.73 | $2.558 | 1,026,963 | |
| $2.54 | +0.15 | +6.3% | $2.385 | $2.55 | $2.31 | 809,332 | |
| $2.39 | +0.15 | +6.7% | $2.25 | $2.41 | $2.21 | 1,203,992 | |
| $2.24 | -0.11 | -4.7% | $2.36 | $2.39 | $2.18 | 1,309,558 | |
| $2.35 | +0.08 | +3.5% | $2.27 | $2.37 | $2.22 | 1,144,000 | |
| $2.27 | -0.15 | -6.2% | $2.40 | $2.509 | $2.235 | 1,763,700 | |
| $2.42 | -0.02 | -0.8% | $2.40 | $2.54 | $2.39 | 1,512,900 | |
| $2.44 | +0.32 | +15.1% | $2.12 | $2.49 | $2.10 | 1,810,000 | |
| $2.12 | +0.135 | +6.8% | $1.99 | $2.175 | $1.96 | 1,231,300 | |
| $1.985 | -0.005 | -0.3% | $2.05 | $2.07 | $1.915 | 1,692,000 | |
| $1.99 | -0.10 | -4.8% | $2.09 | $2.115 | $1.95 | 6,174,400 | |
| $2.09 | -0.07 | -3.2% | $2.15 | $2.22 | $2.06 | 2,257,000 | |
| $2.16 | -0.37 | -14.6% | $2.53 | $2.53 | $2.13 | 2,565,100 | |
| $2.53 | -0.14 | -5.2% | $2.66 | $2.69 | $2.53 | 950,200 | |
| $2.67 | -0.03 | -1.1% | $2.68 | $2.74 | $2.62 | 867,600 | |
| $2.70 | -0.05 | -1.8% | $2.72 | $2.74 | $2.61 | 1,190,400 | |
| $2.75 | -0.03 | -1.1% | $2.77 | $2.835 | $2.72 | 718,000 | |
| $2.78 | -0.08 | -2.8% | $2.88 | $2.90 | $2.74 | 828,100 | |
| $2.86 | -0.10 | -3.4% | $2.96 | $3.04 | $2.775 | 886,000 | |
| $2.96 | -0.10 | -3.3% | $3.11 | $3.11 | $2.92 | 835,000 | |
| $3.06 | -0.135 | -4.2% | $3.20 | $3.20 | $3.04 | 858,300 | |
| $3.195 | +0.055 | +1.8% | $3.13 | $3.225 | $3.075 | 1,497,000 | |
| $3.14 | -0.03 | -0.9% | $3.13 | $3.20 | $3.115 | 1,041,600 | |
| $3.17 | +0.095 | +3.1% | $3.04 | $3.231 | $3.03 | 1,672,800 | |
| $3.075 | -0.245 | -7.4% | $3.32 | $3.34 | $3.02 | 3,046,500 | |
| $3.32 | -0.545 | -14.1% | $3.85 | $3.86 | $3.305 | 3,632,000 | |
| $3.865 | +0.045 | +1.2% | $3.82 | $3.90 | $3.71 | 2,718,600 | |
| $3.82 | -0.01 | -0.3% | $3.91 | $3.965 | $3.815 | 702,900 | |
| $3.83 | +0.04 | +1.1% | $3.84 | $3.885 | $3.78 | 578,000 | |
| $3.79 | -0.01 | -0.3% | $3.81 | $3.88 | $3.75 | 1,640,900 | |
| $3.80 | -0.13 | -3.3% | $3.93 | $4.12 | $3.80 | 1,195,800 | |
| $3.93 | +0.02 | +0.5% | $3.93 | $3.97 | $3.825 | 1,951,900 | |
| $3.91 | +0.13 | +3.4% | $3.86 | $3.94 | $3.70 | 856,600 | |
| $3.78 | -0.14 | -3.6% | $3.93 | $3.98 | $3.74 | 1,169,100 | |
| $3.92 | +0.07 | +1.8% | $3.91 | $4.07 | $3.85 | 2,127,200 | |
| $3.85 | -0.02 | -0.5% | $3.82 | $3.86 | $3.74 | 870,900 | |
| $3.87 | -0.205 | -5.0% | $4.03 | $4.17 | $3.83 | 977,400 | |
| $4.075 | +0.245 | +6.4% | $3.76 | $4.08 | $3.72 | 1,040,600 | |
| $3.83 | 0.00 | 0.0% | $3.82 | $3.85 | $3.79 | 391,900 | |
| $3.83 | -0.04 | -1.0% | $3.90 | $3.90 | $3.774 | 683,700 | |
| $3.87 | -0.07 | -1.8% | $3.96 | $4.075 | $3.822 | 515,300 | |
| $3.94 | +0.12 | +3.1% | $3.78 | $3.95 | $3.77 | 755,300 | |
| $3.82 | -0.19 | -4.7% | $3.98 | $4.00 | $3.81 | 1,065,500 | |
| $4.01 | -0.04 | -1.0% | $4.03 | $4.08 | $3.98 | 641,500 | |
| $4.05 | -0.12 | -2.9% | $4.16 | $4.16 | $4.02 | 672,900 | |
| $4.17 | +0.01 | +0.2% | $4.14 | $4.18 | $4.02 | 702,100 | |
| $4.16 | +0.11 | +2.7% | $4.08 | $4.235 | $4.08 | 1,082,141 | |
| $4.05 | -0.13 | -3.1% | $4.23 | $4.23 | $3.93 | 945,554 | |
| $4.18 | +0.02 | +0.5% | $4.20 | $4.21 | $4.085 | 699,400 | |
| $4.16 | -0.09 | -2.1% | $4.21 | $4.21 | $3.975 | 1,158,000 |
Splits
1 split · NASDAQ:LRMR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation |
- Ticker
- NASDAQ:LRMR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
Latest deck · Nov 9, 2026
Investor Presentation (November 2026)
Investor deck · 38 slides
Latest news
Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
Nov 16, 2026
Closed $3.00 (-0.7%) on Nov 16, 2026
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Nov 9, 2026
Closed $2.69 (+6.3%) on Nov 10, 2026
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
Nov 5, 2026
Closed $2.39 (+3.0%) on Nov 6, 2026
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 4, 2026
Closed $2.32 (-15.9%) on Nov 5, 2026
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Sep 29, 2026
Closed $3.20 (+1.8%) on Sep 30, 2026
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Aug 4, 2026
Closed $4.11 (+3.3%) on Aug 4, 2026
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Jun 29, 2026
Closed $3.20 (-12.6%) on Jun 29, 2026
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Jun 26, 2026
Closed $3.20 (-12.6%) on Jun 29, 2026
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
May 14, 2026
Closed $3.89 (-5.1%) on May 14, 2026
Larimar Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 78 in all · newest Nov 16, 2026 · oldest 2020
- Decks
- 55 decks · latest Nov 9, 2026
Where Larimar Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LRMR · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A2P5PP | LS Exchange | Germany | EUR |
| gettex:ZA71 | gettex | Germany | EUR |
| BOATS:LRMR | BOATS | United States | USD |
| Lang & Schwarz:A2P5PP | Lang & Schwarz | Germany | EUR |
| Tradegate:ZA71 | Tradegate | Germany | EUR |
| Dusseldorf:ZA71 | Dusseldorf | Germany | EUR |
| Frankfurt:ZA71 | Frankfurt | Germany | EUR |
| Stuttgart:ZA71 | Stuttgart | Germany | EUR |
Valuation
Price/book 3.2× against a median of 1.8×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $204.7M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.48
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. · NASDAQ:LRMR | US$328.6M | US$204.7M | n/a | n/a | n/a | 3.2× | n/a | 0.1× | 1.48 |
| Lyell Immunopharma, Inc. · NASDAQ:LYEL | US$339.3M | US$196.5M | n/a | 13,099× | n/a | 1.8× | n/a | 0.2× | 1.51 |
| Avacta Group PLC · LSE:AVCT | US$337.8M | US$337.2M | n/a | 2,281× | n/a | 68.5× | n/a | 5.3× | n/a |
| Inovio Pharmaceuticals, Inc. · NASDAQ:INO | US$329.7M | US$7.56B | n/a | 25,303× | 3.4× | n/a | n/a | n/a | 0.70 |
| CytoDyn Inc. · OTC:CYDY | US$326.4M | US$345.8M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| C4 Therapeutics, Inc. · NASDAQ:CCCC | US$325.7M | US$175.5M | n/a | 5.4× | n/a | 1.4× | −282.2% | 0.2× | 1.46 |
| Laekna, Inc. · HKEX:2105 | US$322.8M | US$154.7M | n/a | 9.7× | n/a | 1.8× | −214.9% | 0.0× | n/a |
| Foresee Pharmaceuticals Co., Ltd. · TPEX:6576 | US$319.8M | US$303.4M | 469× | 21.2× | n/a | 8.3× | 4.8% | 0.3× | n/a |
| GI Innovation, Inc. · KRX:358570 | US$317.8M | US$288.6M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Atea Pharmaceuticals, Inc. · NASDAQ:AVIR | US$317.6M | US$126.6M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 0.86 |
| MapLight Therapeutics, Inc. · NASDAQ:MPLT | US$313.9M | US$29.84M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.28 |
| Median of the others | US$324.2M | US$242.5M | 469× | 1,151× | 3.4× | 1.8× | −214.9% | 0.1× | 1.07 |
Forecasts
9 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.20 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.18 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Carole Ben-Maimon | Chief Executive Officer |
| Michael Celano | CHIEF FINANCIAL OFFICER |
| John Harlow | President and Chief Operating Officer |
| Adrienne Clements-Egan | Vice President, Bioanalytics and Developability |
| Francis Michael Conway | VICE PRESIDENT AND CONTROLLER |
| Frank Nazzario | Vice President, Commercial |
| Jennifer Johansson | Vice President, Legal and Compliance |
| John Berman | Vice President of Finance and Administration |
| Keith E. Lynch | Vice President, CMC Technical Operations |
| Mohamed Hamdani | Vice President, Statistics and Quantitative Sciences |
| Noreen Scherer | Vice President of Clinical Operations |
| Gopi Shankar | Chief Development Officer |
| Rusty Clayton | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Joseph Truitt | BOARD CHAIR |
| Frank E. Thomas | |
| Jeffrey Sherman | |
| Jonathan Leff | |
| Tom Hamilton |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | −0.7% |
| Q2 2026 | Aug 4, 2026 · Before open | +3.3% |
| Q1 2026 | May 14, 2026 · Before open | −5.1% |
| Q4 2025 | Mar 18, 2026 | +2.0% |
| Q3 2025 | Nov 5, 2025 · Before open | −15.3% |
| Q2 2025 | Aug 14, 2025 · Before open | +14.5% |
| Q1 2025 | Apr 30, 2025 · Before open | +10.9% |
| Q4 2024 | Mar 12, 2025 · Before open | +1.5% |
| Q3 2024 | Oct 30, 2024 · Before open | +8.7% |
| Q2 2024 | Aug 7, 2024 · Before open | −6.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −9.4% |
| Q4 2023 | Mar 14, 2024 · After close | +0.1% |
| Q3 2023 | Nov 14, 2023 · After close | +14.4% |
| Q2 2023 | Aug 10, 2023 · Before open | −4.8% |
| Q1 2023 | May 15, 2023 · Before open | −29.1% |
| Q4 2022 | Mar 14, 2023 · Before open | +3.0% |
| Q3 2022 | Nov 10, 2022 · Before open | +3.7% |
| Q2 2022 | Aug 11, 2022 · After close | +7.1% |
| Q1 2022 | May 12, 2022 · Before open | −7.9% |
| Q4 2021 | Mar 25, 2022 · Before open | −0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 38 slides | Nov 9, 2026 |
| Investor Presentation (August 2026) | Investor deck | 40 slides | Aug 4, 2026 |
| Corporate Update (June 2026) | Corporate update | 26 slides | Jun 29, 2026 |
| Investor Presentation (May 2026) | Investor deck | 54 slides | May 14, 2026 |
| Investor Presentation (March 2026) | Investor deck | 54 slides | Mar 9, 2026 |
| Investor Presentation (February 2026) | Investor deck | 54 slides | Feb 24, 2026 |
| Investor Presentation (January 2026) | Investor deck | 54 slides | Jan 12, 2026 |
| Investor Presentation (November 2025) | Investor deck | 52 slides | Nov 10, 2025 |
| Investor Presentation (October 2025) | Investor deck | 52 slides | Oct 14, 2025 |
| Corporate Update (September 2025) | Corporate update | 18 slides | Sep 29, 2025 |
Show 50 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2025) | Investor deck | 58 slides | Aug 14, 2025 |
| Corporate Update (June 2025) | Corporate update | 14 slides | Jun 23, 2025 |
| Investor Presentation (June 2025) | Investor deck | 58 slides | Jun 23, 2025 |
| Investor Presentation (May 2025) | Investor deck | 58 slides | May 5, 2025 |
| Investor Presentation (March 2025) | Investor deck | 58 slides | Mar 24, 2025 |
| Investor Presentation (January 2025) | Investor deck | 59 slides | Jan 10, 2025 |
| Corporate Update (December 2024) | Corporate update | 59 slides | Dec 16, 2024 |
| Investor Presentation (November 2024) | Investor deck | 50 slides | Nov 18, 2024 |
| Investor Presentation (October 2024) | Investor deck | 45 slides | Oct 30, 2024 |
| Investor Presentation (August 2024) | Investor deck | 45 slides | Aug 7, 2024 |
| Investor Presentation (June 2024) | Investor deck | 45 slides | Jun 10, 2024 |
| Investor Presentation (May 2024) | Investor deck | 44 slides | May 20, 2024 |
| Investor Presentation (May 2024) | Investor deck | 46 slides | May 9, 2024 |
| Investor Presentation (March 2024) | Investor deck | 47 slides | Mar 11, 2024 |
| Leerink Partners Global Healthcare Conference 2024 | Conference | 19 slides | Mar 11, 2024 |
| Corporate Update (February 2024) | Corporate update | 22 slides | Feb 12, 2024 |
| Investor Presentation (February 2024) | Investor deck | 45 slides | Feb 12, 2024 |
| Investor Presentation (November 2023) | Investor deck | 44 slides | Nov 14, 2023 |
| Investor Presentation (August 2023) | Investor deck | 44 slides | Aug 14, 2023 |
| Corporate Update (July 2023) | Corporate update | 12 slides | Jul 25, 2023 |
| Investor Presentation (June 2023) | Investor deck | 43 slides | Jun 1, 2023 |
| Corporate Update (May 2023) | Corporate update | 15 slides | May 15, 2023 |
| Investor Presentation (March 2023) | Investor deck | 33 slides | Mar 14, 2023 |
| Investor Presentation (January 2023) | Investor deck | 33 slides | Jan 9, 2023 |
| Investor Presentation (November 2022) | Investor deck | 31 slides | Nov 10, 2022 |
| Investor Presentation (October 2022) | Investor deck | 32 slides | Oct 20, 2022 |
| Corporate Update (September 2022) | Corporate update | 31 slides | Sep 14, 2022 |
| Investor Presentation (August 2022) | Investor deck | 34 slides | Aug 11, 2022 |
| Investor Presentation (May 2022) | Investor deck | 34 slides | May 12, 2022 |
| Investor Presentation (March 2022) | Investor deck | 34 slides | Mar 25, 2022 |
| Investor Presentation (February 2022) | Investor deck | 34 slides | Feb 28, 2022 |
| Investor Presentation (November 2021) | Investor deck | 36 slides | Nov 12, 2021 |
| Investor Presentation (August 2021) | Investor deck | 36 slides | Aug 12, 2021 |
| Investor Presentation (July 2021) | Investor deck | 36 slides | Jul 1, 2021 |
| Investor Presentation (May 2021) | Investor deck | 36 slides | May 18, 2021 |
| Corporate Update (May 2021) | Corporate update | 22 slides | May 11, 2021 |
| Investor Presentation (December 2020) | Investor deck | 31 slides | Dec 8, 2020 |
| Investor Presentation (November 2020) | Investor deck | 28 slides | Nov 10, 2020 |
| Investor Presentation (August 2020) | Investor deck | 23 slides | Aug 6, 2020 |
| Investor Presentation (June 2020) | Investor deck | 21 slides | Jun 3, 2020 |
This page holds 50 of 55 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock and pre-funded warrants Announced: US$75M · J.P. Morgan +1 Dealers: J.P. Morgan (co-lead), Guggenheim Securities (co-lead) Use of proceeds: Development of nomlabofusp, working capital and general corporate purposes, including R&D and commercialization expenses | Feb 25, 2026 |
| Public offering of common stock Closed: US$69M raised · US$3.2 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Truist Securities (co-lead), William Blair (co-lead) Use of proceeds: Development of nomlabofusp and other pipeline candidates, working capital and general corporate purposes including R&D and pre-commercialization | Jul 31, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as ZAFGEN, INC. Priced at US$16.00 a share on Jun 18, 2014.
- Price
- US$16.00 a share
- Shares offered
- 6,000,000 shares of common stock
- Offering size
- US$96 million
- Underwriters' option
- Up to 900,000 more shares
- Underwriters
- Leerink Partners, Cowen and Company, Canaccord Genuity, JMP Securities · In the order on the cover
- Shares delivered
- On or about Jun 24, 2014
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 31, 2014 |
| Filed publicly | Apr 18, 2014 |
| Amended 5 times | Newest Jun 16, 2014 |
| Shares registered with an exchange | Jun 18, 2014 |
| Declared effective by the SEC | Jun 18, 2014 |
| Final prospectus, with the price | Jun 19, 2014 |
Filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 20, 2014 |
| 424B4 · Prospectus | Jun 19, 2014 |
| EFFECT · Notice that a registration is effective | Jun 18, 2014 |
| S-1MEF · Registration of more shares for the same offering | Jun 18, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Jun 18, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 18, 2014 |
| CORRESP · Letter to the SEC | Jun 16, 2014 |
| CORRESP · Letter to the SEC | Jun 16, 2014 |
| S-1/A · Registration statement, amended | Jun 16, 2014 |
| S-1/A · Registration statement, amended | Jun 5, 2014 |
All 18 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jun 2, 2014 |
| S-1/A · Registration statement, amended | May 2, 2014 |
| S-1/A · Registration statement, amended | Apr 28, 2014 |
| S-1 · Registration statement | Apr 18, 2014 |
| UPLOAD · Letter from the SEC | Mar 27, 2014 |
| DRS/A · Draft registration statement, amended | Mar 14, 2014 |
| UPLOAD · Letter from the SEC | Feb 28, 2014 |
| DRS · Draft registration statement | Jan 31, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 19, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 350.0K | 318.0K | 311.0K | 272.0K | 326.0K | 155.0K | 78.0K | 261.0K | 188.0K | 212.0K |
| Gross profit | -350.0K | -318.0K | -311.0K | -272.0K | -326.0K | -155.0K | -78.0K | -261.0K | -188.0K | -212.0K |
| Research and development | 154.2M | 73.3M | 27.7M | 24.3M | 38.4M | 31.4M | 20.8M | 47.9M | 40.8M | 39.9M |
| Selling, general and administrative | 18.3M | 17.6M | 14.1M | 12.3M | 12.1M | 11.4M | 2.42M | 1.52M | 12.2M | 18.3M |
| Operating income | -172.5M | -90.9M | -41.8M | -36.5M | -50.5M | -42.8M | -23.2M | -61.1M | -53.0M | -58.2M |
| Depreciation and amortization | 350.0K | 318.0K | 311.0K | 318.0K | 326.0K | 155.0K | 78.0K | 261.0K | 188.0K | 212.0K |
| EBITDA | -172.1M | -90.6M | -41.4M | -36.2M | -50.1M | -42.6M | -23.1M | -60.9M | -52.8M | -58.0M |
| Interest expense | 318.0K | 326.0K | 0 | 1.77M | 1.90M | 165.0K | 529.0K | |||
| Income before tax | -165.7M | -80.6M | -36.9M | -35.4M | -50.6M | -42.5M | -23.2M | -61.4M | -52.0M | -57.9M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -165.7M | -80.6M | -36.9M | -35.4M | -50.6M | -42.5M | -23.1M | -61.4M | -52.0M | -57.9M |
| Earnings per share, basic | -1.99 | -1.32 | -0.84 | -1.37 | -2.95 | -3.57 | -3.80 | -1.90 | -1.90 | -2.12 |
| Earnings per share, diluted | -1.32 | -0.84 | -1.37 | -2.95 | -3.57 | -3.80 | -1.90 | -1.90 | -2.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 85.4M | 33.2M | 26.7M | 26.8M | 70.1M | 68.1M | 1.01M | 49.3M | 40.8M | 32.4M |
| Short-term investments | 51.4M | 150.2M | 60.0M | 91.6M | 0 | 24.5M | 43.0M | 68.7M | 61.3M | 96.8M |
| Receivables | 747.0K | 1.05M | 332.0K | 208.0K | 32.0K | 158.0K | 1.54M | 946.0K | 347.0K | |
| Inventory | -208.0K | -32.0K | 3.16M | 1 | ||||||
| Current assets | 142.0M | 195.3M | 90.2M | 120.7M | 72.2M | 98.0M | 4.75M | 121.3M | 104.9M | 130.9M |
| Property, plant and equipment | 622.0K | 881.0K | 684.0K | 831.0K | 1.05M | 1.04M | 274.0K | 375.0K | 528.0K | 661.0K |
| Total assets | 145.8M | 200.2M | 95.9M | 126.4M | 78.7M | 104.7M | 5.20M | 121.8M | 105.5M | 131.6M |
| Accounts payable | 5.22M | 2.42M | 1.28M | 1.69M | 1.66M | 2.63M | 3.54M | 3.59M | 3.02M | 2.57M |
| Current liabilities | 64.8M | 24.4M | 9.51M | 10.7M | 8.85M | 8.99M | 5.89M | 13.3M | 7.29M | 9.89M |
| Long-term debt | 8.46M | 15.2M | 20.0M | |||||||
| Total debt | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M | 6.52M | 14.5M | 20.0M | 20.0M | 3.18M |
| Total liabilities | 67.8M | 28.4M | 14.2M | 15.5M | 14.3M | 15.0M | 5.89M | 28.5M | 27.3M | 9.89M |
| Shareholders' equity | 78.1M | 171.8M | 81.7M | 110.9M | 64.4M | 89.7M | -694.0K | 2.91M | 78.2M | 121.7M |
| Shares outstanding | 83.1M | 63.8M | 43.9M | 43.3M | 17.7M | 15.4M | 6.09M | 37.3M | 27.5M | 27.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -113.2M | -70.8M | -33.5M | -27.6M | -42.1M | -42.2M | -22.7M | -51.5M | -43.8M | -52.0M |
| Capital spending | -91.0K | -515.0K | -164.0K | -100.0K | -333.0K | -62.0K | -83.0K | -108.0K | -55.0K | -660.0K |
| Free cash flow | -113.3M | -71.3M | -33.6M | -27.7M | -42.4M | -42.3M | -22.8M | -51.6M | -43.8M | -52.6M |
| Cash from investing | 100.3M | -85.4M | 33.4M | -91.0M | 24.2M | 17.1M | -83.0K | -6.87M | 35.6M | 51.4M |
| Cash from financing | 65.1M | 161.9M | 30.0K | 75.3M | 19.9M | 93.6M | 19.4M | 66.9M | 16.6M | -2.71M |
| Share buybacks | 75.3M | 75.6M | 194.0K | 67.2M | 195.0K | 220.0K | ||||
| Change in cash | 52.2M | 5.74M | -76.0K | -43.3M | 1.95M | 68.5M | -3.39M | 8.55M | 8.43M | -3.24M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 16, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 29, 2026 | Current report | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 8-K · Current report | May 19, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 20, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 26, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Feb 25, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 24, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 22, 2026 | Financing | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 8-K · Current report | Dec 17, 2025 | Financing | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| 8-K · Current report | Sep 29, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 29, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 31, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 31, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 30, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 29, 2025 | Results | SEC |
| 424B5 · Prospectus | Jul 29, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 5, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Apr 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 16, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 11, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 24, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 27, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| 8-K · Current report | Nov 18, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 6, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 30, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 8-K · Current report | Jun 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 8-K · Current report | May 31, 2024 | Meeting outcome | SEC |
| 8-K · Current report | May 30, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 28, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 22, 2024 | Other filings | SEC |
| 8-K · Current report | May 20, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | May 16, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 12, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 15, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 14, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 14, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 14, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 14, 2024 | Results | SEC |
| 8-K · Current report | Mar 11, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 26, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 16, 2024 | Material contract | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 16, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 15, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 14, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 14, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 13, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 12, 2024 | Results | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 5, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 3, 2023 | Management or board change | SEC |
| SC 13G · Big-stake notice | Aug 18, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 8-K · Current report | Jul 25, 2023 | Current report | SEC |
| 144 · Notice of proposed sale | Jul 24, 2023 | Other filings | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 17, 2023 | Current report | SEC |
| 8-K · Current report | Jun 1, 2023 | Current report | SEC |
| 4 · Change in ownership | May 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| 8-K · Current report | May 12, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 11, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 11, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 6, 2023 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 16, 2023 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 14, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 14, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 14, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 14, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 9, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 7, 2023 | Current report | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 20, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 9, 2023 | Current report | SEC |
This page holds 200 of 710 filings. Open Filings
Cap table
Built by 6ix from Larimar Therapeutics, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 104,634,619
- Fully diluted
- 104,634,619
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 104,634,619 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 104,634,619 |
| Sep 30, 2026 | 104,634,619 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Flynn Other companies: Lite Strategy, Inc. (Director · Since at least Oct 31, 2023); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); Oruka Therapeutics, Inc. (Director · Jan 30, 2024 – Jan 30, 2024 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past) | Director · Since at least May 28, 2020 |
| Robert J Perez Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Immunocore Holdings plc (Director · Jan 2, 2024 – Jan 2, 2024 · Past); Third Harmonic Bio Inc. (Director · Sep 14, 2022 – Mar 6, 2023 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 22, 2023 · Past); Cogent Biosciences, Inc. (Director · Mar 28, 2018 – Jun 14, 2019 · Past); Spark Therapeutics Inc (Director · Jan 3, 2018 – Dec 17, 2019 · Past); Decoy Therapeutics Inc. (Director · Sep 2, 2015 – Jul 26, 2017 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 22, 2017 · Past); AMAG Pharmaceuticals Inc (Director · Jan 26, 2009 – May 16, 2019 · Past); Cubist Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 3, 2006 – Jan 21, 2015 · Past) | Director · Sep 24, 2015 – Jun 26, 2019 · Past |
| Jonathan Leff Other companies: BiomX Inc. (Director · Mar 15, 2024 – Apr 14, 2025 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Protara Therapeutics, Inc. (Director · Aug 2, 2017 – Jun 8, 2018 · Past); AveXis Inc (Director · Feb 10, 2016 – Feb 10, 2016 · Past); Alpine Immune Sciences Inc (Director · Jun 16, 2015 – Sep 11, 2015 · Past); InterMune Inc (EVP, Research & Development · Feb 27, 2012 – Sep 29, 2014 · Past) | Director · Since at least May 28, 2020 |
| Kevin P Starr Other companies: MyoKardia Inc (Director · Oct 28, 2015 – Mar 7, 2018 · Past); Global Blood Therapeutics Inc (Director · Aug 11, 2015 – Aug 17, 2015 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Jun 15, 2023 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Feb 19, 2015 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2007 – Jun 2, 2017 · Past); Human Genome Sciences Inc (Director · May 3, 2007 – Jul 10, 2007 · Past) | Director · Jun 18, 2014 – Sep 24, 2015 · Past |
| Alicia Secor Other companies: Zevra Therapeutics, Inc. (Director, Audit Committee, Compensation Committee · Since at least Dec 2, 2025); G1 Therapeutics Inc (Director · Jun 17, 2021 – Sep 18, 2024 · Past); Orchard Therapeutics PLC (Director · Jan 1, 2020 – Jan 24, 2024 · Past); GW Pharmaceuticals plc (Director · Oct 1, 2018 – May 5, 2021 · Past); Juniper Pharmaceuticals Inc (President and CEO, Director · Aug 1, 2016 – Aug 14, 2018 · Past) | Chief Commercial Officer · Mar 31, 2016 – Mar 31, 2016 · Past |
| Thomas Daniel Other companies: Gossamer Bio, Inc. (Director · Since at least Feb 7, 2019); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past); Juno Therapeutics Inc (Director · Aug 11, 2015 – Mar 5, 2018 · Past); Epizyme Inc (Director · May 30, 2013 – May 30, 2013 · Past); Celgene Corporation (see remarks · Feb 15, 2012 – Dec 31, 2015 · Past) | Director · Mar 3, 2016 – May 12, 2021 · Past |
| Jeffrey Sherman Other companies: Xeris Biopharma Holdings, Inc. (Director · Since at least Oct 5, 2021); Strongbridge Biopharma plc (Director · Jan 1, 2018 – Oct 5, 2021 · Past); Horizon Pharma PLC (EVP and Chief Medical Officer · Jul 28, 2011 – Mar 23, 2018 · Past); Idm Pharma Inc (Sr. VP, R & D and CMO · Aug 29, 2007 – Apr 3, 2008 · Past) | Director · Since at least Oct 3, 2023 |
| Dennis Kim Other companies: Skye Bioscience, Inc. (Chief Medical Officer · Aug 21, 2019 – Aug 7, 2020 · Past); Sesen Bio Inc (Chief Medical Officer · Dec 3, 2018 – Dec 3, 2018 · Past); Orexigen Therapeutics Inc (Sr. VP, Corporate Development · Feb 27, 2009 – Apr 23, 2009 · Past) | Chief Medical Officer · Jun 18, 2014 – Jan 22, 2019 · Past |
| Frank E Thomas Other companies: Spero Therapeutics, Inc. (Director · Since at least Nov 1, 2017); Orchard Therapeutics PLC (See Remarks · Jan 1, 2020 – Jan 24, 2024 · Past); AMAG Pharmaceuticals Inc (President & COO · Feb 23, 2017 – Feb 23, 2017 · Past) | Director · Since at least Jun 30, 2016 |
| John L. LaMattina Other companies: Ligand Pharmaceuticals Incorporated (Director · Since at least May 31, 2012); Immunome, Inc. (Director · Oct 1, 2020 – Jun 8, 2023 · Past); Human Genome Sciences Inc (Director · May 17, 2012 – Jul 30, 2012 · Past) | Director · Jun 18, 2014 – Jun 26, 2019 · Past |
All 31 people
| Person | Seat |
|---|---|
| Michael Celano Other companies: Recro Pharma Inc (Chief Operating Officer · Jul 5, 2016 – Jan 18, 2019 · Past); Kensey Nash Corp (Chief Financial Officer · Mar 10, 2009 – Jun 22, 2012 · Past); OraSure Technologies, Inc. (Director · Oct 4, 2006 – Aug 12, 2022 · Past) | Chief Financial Officer · Since at least May 28, 2020 |
| Peter Barrett Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026); Synlogic Inc (Chairman, Partner, Atlas Venture · Since at least Jun 9, 2022); Revvity, Inc. (Partner, Atlas Venture · Since at least May 6, 2022) | Director · May 10, 2022 – May 10, 2022 · Past |
| Carole Ben-Maimon Other companies: Teligent Inc (Director · Mar 29, 2016 – Jul 21, 2021 · Past); Impax Laboratories Inc (President, Global Pharm. · Sep 6, 2011 – May 14, 2014 · Past) | President and CEO, Director · Since at least May 28, 2020 |
| Frank E. Thomas Other companies: Spero Therapeutics, Inc. (Chairman of the Board; Audit Committee Chair · Since at least Apr 28, 2025) | Director · Since at least Nov 4, 2026 |
| John B Harlow Jr Other companies: Esperion Therapeutics, Inc. (Chief Commercial Officer · Since at least Nov 17, 2025) | President and COO · Since at least Sep 29, 2026 |
| Joseph Truitt Other companies: Century Therapeutics, Inc. (Director · Since at least Sep 9, 2026) | BOARD CHAIR · Since at least May 10, 2022 |
| Thomas E Hughes Other companies: Viridian Therapeutics, Inc. (Director · Feb 13, 2017 – May 21, 2020 · Past) | See Remarks, Director · Jun 18, 2014 – Jun 28, 2018 · Past |
| Adrienne Clements-Egan | Vice President, Bioanalytics and Developability · Since at least Nov 5, 2026 |
| Francis Michael Conway | VICE PRESIDENT AND CONTROLLER · Since at least Nov 5, 2026 |
| Frank Nazzario | Vice President, Commercial · Since at least Nov 4, 2026 |
| Gopi Shankar | Chief Development Officer · Since at least Feb 7, 2023 |
| Jennifer Johansson | Vice President, Legal and Compliance · Since at least Nov 5, 2026 |
| John Berman | Vice President of Finance and Administration · Since at least Nov 5, 2026 |
| John Harlow | President and Chief Operating Officer · Since Sep 29, 2026 |
| Keith E. Lynch | Vice President, CMC Technical Operations · Since at least Nov 5, 2026 |
| Mohamed Hamdani | Vice President, Statistics and Quantitative Sciences · Since at least Nov 5, 2026 |
| Noreen Scherer | Vice President of Clinical Operations · Since at least Nov 5, 2026 |
| Russell Clayton | Chief Medical Officer · Since at least Jul 17, 2023 |
| Rusty Clayton | Chief Medical Officer · Since at least Feb 24, 2026 |
| Tom Hamilton | Director · Since at least Jul 8, 2026 |
| Wendy Everett | Director · Jun 26, 2019 – Jun 26, 2019 · Past |
Log in to ask 6ix AI your own questions about Larimar Therapeutics, Inc.